Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites

被引:67
作者
Stuyver, LJ
McBrayer, TR
Tharnish, PM
Hassan, AEA
Chu, CK
Pankiewicz, KW
Watanabe, KA
Schinazi, RF
Otto, MJ
机构
[1] Pharmasset Inc, Tucker, GA 30084 USA
[2] Univ Georgia, Coll Pharm, Athens, GA 30602 USA
[3] Emory Univ, Sch Med, Vet Affairs Med Ctr, Decatur, GA 30033 USA
[4] Emory Univ, Sch Med, Dept Pediat, Decatur, GA 30033 USA
关键词
D O I
10.1128/JVI.77.19.10689-10694.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Treatment with antimetabolites results in chemically induced low nucleoside triphosphate pools and cell cycle arrest in exponentially growing cells. Since steady-state levels of hepatitis C virus (HCV) replicon RNA were shown to be dependent on exponential growth of Huh-7 cells, the effects of antimetabolites for several nucleoside biosynthesis pathways on cell growth and HCV RNA levels were investigated. A specific anti-HCV replicon effect was defined as (i) minimal interference with the exponential cell growth, (ii) minimal reduction in cellular host RNA levels, and (iii) reduction of the HCV RNA copy number per cell compared to that of the untreated control. While most antimetabolites caused a cytostatic effect on cell growth, only inhibitors of the de novo pyrimidine ribonucleoside biosynthesis mimicked observations seen in confluent replicon cells, i.e., cytostasis combined with a sharp decrease in replicon copy number per cell. These results suggest that high levels of CTP and UTP are critical parameters for maintaining the steady-state level replication of HCV replicon in Huh-7 cells.
引用
收藏
页码:10689 / 10694
页数:6
相关论文
共 31 条
[1]   Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors [J].
Balzarini, J .
PHARMACOLOGY & THERAPEUTICS, 2000, 87 (2-3) :175-187
[2]   Replication of hepatitis C virus [J].
Bartenschlager, R ;
Lohmann, V .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :1631-1648
[3]   Novel cell culture systems for the hepatitis C virus [J].
Bartenschlager, R ;
Lohmann, V .
ANTIVIRAL RESEARCH, 2001, 52 (01) :1-17
[4]  
BUDMAN D, 1977, CANCER TREAT REP, V61, P1733
[5]  
CARROLL DS, 1979, CANCER TREAT REP, V63, P139
[6]   Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs [J].
Carroll, SS ;
Tomassini, JE ;
Bosserman, M ;
Getty, K ;
Stahlhut, MW ;
Eldrup, AB ;
Bhat, B ;
Hall, D ;
Simcoe, AL ;
LaFemina, R ;
Rutkowski, CA ;
Wolanski, B ;
Yang, ZC ;
Migliaccio, G ;
De Francesco, R ;
Kuo, LC ;
MacCoss, M ;
Olsen, DB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (14) :11979-11984
[7]   Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons [J].
Cheney, IW ;
Lai, VCH ;
Zhong, WD ;
Brodhag, T ;
Dempsey, S ;
Lim, C ;
Hong, Z ;
Lau, JYN ;
Tam, RC .
JOURNAL OF VIROLOGY, 2002, 76 (21) :11148-11154
[8]  
CHENG E, 1979, CANCER TREAT REP, V63, P2047
[9]   Heterogeneous nuclear ribonucleoprotein I (hnRNP-I/PTB) selectively binds the conserved 3′ terminus of hepatitis C viral RNA [J].
Chung, RT ;
Kaplan, LM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 254 (02) :351-362
[10]  
CREAGAN ET, 1977, CANCER TREAT REP, V61, P491